|
|||
|
Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
Shannon HK Kim, David Habashy, Sana Pathan, Vincent Tse, Ruth Collins, Lewis Chan
Int Neurourol J. 2016;20(1):40-46. Published online 2016 Mar 16
DOI: https://doi.org/10.5213/inj.1630450.225 |
|||
|
Citations to this article as recorded by  Variation in the Definitions of Urinary Retention in Studies of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder: A Narrative Systematic Review
Stephanie Stavrou, Jessica A. Paynter, Thomas Carins, Kirby R. Qin, Janelle Brennan
Neurourology and Urodynamics.2025; 44(4): 860. CrossRef The use of intradetrusor botulinum toxin in the geriatric population
William Chui, Alvaro Bazo, Henry H. Yao, Joshua Kealey, Lana Pepdjonovic, Helen E. O'Connell, Johan Gani, Richard Parkinson
BJUI Compass.2025;[Epub] CrossRef Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
Yin-Chien Ou, Yao-Lin Kao, Yi-Hui Ho, Kuan-Yu Wu, Hann-Chorng Kuo
Toxins.2023; 15(2): 95. CrossRef Bladder Dysfunction in Older Adults: The Botulinum Toxin Option
Yao-Lin Kao, Yin-Chien Ou, Hann-Chorng Kuo
Drugs & Aging.2022; 39(6): 401. CrossRef Effect of mesenchymal stem cells on induced skeletal muscle chemodenervation atrophy in adult male albino rats
Azza S. Shehata, Nabila M. Al-Ghonemy, Samah M. Ahmed, Samar R. Mohamed
The International Journal of Biochemistry & Cell Biology.2017; 85: 135. CrossRef
|
